Tracey Technologies Announces New Features with Version 7.0 Upgrade |...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

Philadelphia Works Names First Female Chief Operating Officer • Build community with shared future, create better world • Statement from the Chief Public Health Officer of Canada on World TB Day • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting • National University Receives 2023 Military Friendly® Gold Designation • AI-Powered Stylitics Launches Latest Platform with First-of-Its-Kind Automated Styling Technology for Retailers • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC, a partner of Veterans for Trump • Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges • 30+ Health Leaders Explore Strategies to Ease Hospital-to-Home Patient Transitions • Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B

Tracey Technologies Announces New Features with Version 7.0 Upgrade

HOUSTON , February 02 /Businesswire/ - Tracey Technologies announced the release of iTrace Prime, an upgraded software for the iTrace Ray Tracing Aberrometer and Corneal Topographer from a trusted leader in ophthalmic technology development. This new software version (7.0) adds many valuable new features that improve the range of information able to be gathered from a single device.

The “Prime Dashboard” includes two new indices: the Corneal Performance Index (CPI™) and the Quality of Vision Index (QVI™) to the proprietary Dysfunctional Lens Index (DLI™). This additional data provides practitioners an even more comprehensive picture of patients’ eyesight while enhancing their ability to identify the source of vision problems, making it easier to plan the best treatment option for every patient.

The iTrace Prime upgrade also includes Tear Film Analysis, a new capability that surgeons have been waiting for. This latest addition to iTrace will record many images of the ocular surface for 12 seconds starting immediately after a blink, which can then reveal the local shape and sharpness changes of Placido rings. A proprietary algorithm then generates a number from 0-10 — the Tear Film Index (TFI™) — which assesses the degree to which the effects of Dry Eye Disease (DED) are impacting a patient’s vision.

“We’re proud to continue developing iTrace capabilities as we stay at the leading edge of the vision industry,” said Ray Sievert, Tracey’s Executive Vice President of Sales and Marketing. “The quality and stability of the ocular surface is a critical component of understanding a patient’s vision issues as we strive to help surgeons provide exceptional outcomes after eye surgery. We’re proud that iTrace Prime is making it possible for doctors to utilize even more needed information from a single device.”

To learn more about iTrace Prime, contact Tracey Technologies at sales@traceytech.com or click here.

About the iTrace

Tracey Technologies developed the iTrace more than a decade ago to help uncover the underlying causes of “vision mysteries,” educate patients, and precisely plan a range of vision correction procedures. As the only device to use true Ray Tracing to objectively measure the way light enters the eye, top cataract and refractive surgeons have relied on the iTrace to help them provide the best possible outcomes to their patients for many years. To learn more about the iTrace, visit www.traceytechnologies.com.